Home › Funds › EMERALD MUTUAL FUND ADVISERS TRUST › SYRE

EMERALD MUTUAL FUND ADVISERS TRUST position in SYRE

SPYRE THERAPEUTICS INC · Health Care

EMERALD MUTUAL FUND ADVISERS TRUST reported holding 366,129 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$32.6M, representing 1.33% of its reported portfolio and ranking #18 among its reported holdings. EMERALD MUTUAL FUND ADVISERS TRUST has disclosed SYRE holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)366.13K sh
Reported value held$32.60M
Portfolio Weight1.33%
First reportedQ3 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How EMERALD MUTUAL FUND ADVISERS TRUST's SYRE position evolved

EMERALD MUTUAL FUND ADVISERS TRUST first disclosed a stake in SYRE in Q3 2024 at 253,550 shares (US$7.5M). The position peaked in Q2 2026 at 401,271 shares, worth US$35.6M. Across 9 filings, EMERALD MUTUAL FUND ADVISERS TRUST increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 366,129 shares valued at US$32.6M — a reduction of -35,142 shares quarter over quarter.. Notable position changes include a 52% increase in Q4 2024 (shares fell 31% over the following quarter), a 34% increase in Q4 2025 (shares rose 54% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 253.55K $7.46M New
Q4 2024 386.38K $9.00M Add
Q1 2025 389.42K $6.28M Add
Q2 2025 329.43K $4.93M Reduce
Q3 2025 308.21K $5.17M Reduce
Q4 2025 412.37K $13.51M Add
Q1 2026 408.11K $20.59M Reduce
Q2 2026 401.27K $35.62M Reduce
Q3 2026 366.13K $32.60M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 66 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has EMERALD MUTUAL FUND ADVISERS TRUST held SYRE?

EMERALD MUTUAL FUND ADVISERS TRUST has disclosed SYRE holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is EMERALD MUTUAL FUND ADVISERS TRUST's current position in SYRE?

As of Q3 2026, EMERALD MUTUAL FUND ADVISERS TRUST holds 366.13K shares of SYRE (SPYRE THERAPEUTICS INC), valued at $32.60M, representing 1.33% of its reported portfolio and ranking #18.

Has EMERALD MUTUAL FUND ADVISERS TRUST been buying or selling SYRE?

In the latest 13F filing (Q3 2026), EMERALD MUTUAL FUND ADVISERS TRUST reduced its position in SYRE. The position peaked in Q2 2026 at 401.27K shares.

Which other funds hold SYRE?

Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 66 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.